vs
Side-by-side financial comparison of UNIVERSAL DISPLAY CORP \PA\ (OLED) and PTC THERAPEUTICS, INC. (PTCT). Click either name above to swap in a different company.
PTC THERAPEUTICS, INC. is the larger business by last-quarter revenue ($164.7M vs $142.2M, roughly 1.2× UNIVERSAL DISPLAY CORP \PA\). UNIVERSAL DISPLAY CORP \PA\ runs the higher net margin — 25.2% vs -82.0%, a 107.2% gap on every dollar of revenue. On growth, UNIVERSAL DISPLAY CORP \PA\ posted the faster year-over-year revenue change (-14.5% vs -22.7%). Over the past eight quarters, UNIVERSAL DISPLAY CORP \PA\'s revenue compounded faster (-5.3% CAGR vs -11.5%).
Universal Display Corporation is a developer and manufacturer of organic light emitting diode (OLED) technologies and materials, and it is a provider of services to the display and lighting industries.
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
OLED vs PTCT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $142.2M | $164.7M |
| Net Profit | $35.9M | $-135.0M |
| Gross Margin | 74.6% | — |
| Operating Margin | 30.1% | -43.3% |
| Net Margin | 25.2% | -82.0% |
| Revenue YoY | -14.5% | -22.7% |
| Net Profit YoY | -44.3% | -104.8% |
| EPS (diluted) | $0.76 | $-1.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $142.2M | — | ||
| Q4 25 | $172.9M | $164.7M | ||
| Q3 25 | $139.6M | $211.0M | ||
| Q2 25 | $171.8M | $178.9M | ||
| Q1 25 | $166.3M | $1.2B | ||
| Q4 24 | $162.3M | $213.2M | ||
| Q3 24 | $161.6M | $196.8M | ||
| Q2 24 | $158.5M | $186.7M |
| Q1 26 | $35.9M | — | ||
| Q4 25 | $66.3M | $-135.0M | ||
| Q3 25 | $44.0M | $15.9M | ||
| Q2 25 | $67.3M | $-64.8M | ||
| Q1 25 | $64.4M | $866.6M | ||
| Q4 24 | $46.0M | $-65.9M | ||
| Q3 24 | $66.9M | $-106.7M | ||
| Q2 24 | $52.3M | $-99.2M |
| Q1 26 | 74.6% | — | ||
| Q4 25 | 76.1% | — | ||
| Q3 25 | 74.6% | — | ||
| Q2 25 | 77.2% | — | ||
| Q1 25 | 77.1% | — | ||
| Q4 24 | 77.0% | — | ||
| Q3 24 | 77.8% | — | ||
| Q2 24 | 75.8% | — |
| Q1 26 | 30.1% | — | ||
| Q4 25 | 38.9% | -43.3% | ||
| Q3 25 | 30.9% | 1.4% | ||
| Q2 25 | 39.9% | -19.5% | ||
| Q1 25 | 41.9% | 82.5% | ||
| Q4 24 | 32.3% | -76.2% | ||
| Q3 24 | 41.5% | -27.7% | ||
| Q2 24 | 35.6% | -21.5% |
| Q1 26 | 25.2% | — | ||
| Q4 25 | 38.4% | -82.0% | ||
| Q3 25 | 31.5% | 7.5% | ||
| Q2 25 | 39.2% | -36.3% | ||
| Q1 25 | 38.8% | 73.7% | ||
| Q4 24 | 28.4% | -30.9% | ||
| Q3 24 | 41.4% | -54.2% | ||
| Q2 24 | 33.0% | -53.1% |
| Q1 26 | $0.76 | — | ||
| Q4 25 | $1.40 | $-1.63 | ||
| Q3 25 | $0.92 | $0.20 | ||
| Q2 25 | $1.41 | $-0.83 | ||
| Q1 25 | $1.35 | $10.04 | ||
| Q4 24 | $0.96 | $-0.85 | ||
| Q3 24 | $1.40 | $-1.39 | ||
| Q2 24 | $1.10 | $-1.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $516.4M | $1.9B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $-205.3M |
| Total Assets | $1.9B | $2.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $516.4M | — | ||
| Q4 25 | $602.4M | $1.9B | ||
| Q3 25 | $603.0M | $1.7B | ||
| Q2 25 | $525.2M | $2.0B | ||
| Q1 25 | $571.3M | $2.0B | ||
| Q4 24 | $492.7M | $1.1B | ||
| Q3 24 | $551.6M | $1.0B | ||
| Q2 24 | $530.5M | $1.1B |
| Q1 26 | — | — | ||
| Q4 25 | $1.8B | $-205.3M | ||
| Q3 25 | $1.7B | $-155.8M | ||
| Q2 25 | $1.7B | $-206.5M | ||
| Q1 25 | $1.7B | $-185.8M | ||
| Q4 24 | $1.6B | $-1.1B | ||
| Q3 24 | $1.6B | $-1.1B | ||
| Q2 24 | $1.5B | $-980.2M |
| Q1 26 | $1.9B | — | ||
| Q4 25 | $2.0B | $2.9B | ||
| Q3 25 | $1.9B | $2.6B | ||
| Q2 25 | $1.9B | $2.6B | ||
| Q1 25 | $1.9B | $2.7B | ||
| Q4 24 | $1.8B | $1.7B | ||
| Q3 24 | $1.8B | $1.8B | ||
| Q2 24 | $1.8B | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.9M | $-34.3M |
| Free Cash FlowOCF − Capex | — | $-36.6M |
| FCF MarginFCF / Revenue | — | -22.3% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | 3.03× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $702.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $108.9M | — | ||
| Q4 25 | $31.1M | $-34.3M | ||
| Q3 25 | $97.2M | $-66.3M | ||
| Q2 25 | $51.9M | $-58.3M | ||
| Q1 25 | $30.6M | $870.1M | ||
| Q4 24 | $34.7M | $-30.0M | ||
| Q3 24 | $79.9M | $-77.0M | ||
| Q2 24 | $67.0M | $-71.5M |
| Q1 26 | — | — | ||
| Q4 25 | $15.1M | $-36.6M | ||
| Q3 25 | $84.3M | $-69.7M | ||
| Q2 25 | $37.5M | $-59.6M | ||
| Q1 25 | $17.5M | $868.4M | ||
| Q4 24 | $22.0M | $-33.8M | ||
| Q3 24 | $66.2M | $-77.5M | ||
| Q2 24 | $57.9M | $-78.8M |
| Q1 26 | — | — | ||
| Q4 25 | 8.7% | -22.3% | ||
| Q3 25 | 60.4% | -33.1% | ||
| Q2 25 | 21.8% | -33.3% | ||
| Q1 25 | 10.5% | 73.8% | ||
| Q4 24 | 13.6% | -15.8% | ||
| Q3 24 | 41.0% | -39.4% | ||
| Q2 24 | 36.5% | -42.2% |
| Q1 26 | — | — | ||
| Q4 25 | 9.3% | 1.4% | ||
| Q3 25 | 9.2% | 1.6% | ||
| Q2 25 | 8.4% | 0.7% | ||
| Q1 25 | 7.9% | 0.1% | ||
| Q4 24 | 7.8% | 1.8% | ||
| Q3 24 | 8.4% | 0.3% | ||
| Q2 24 | 5.8% | 4.0% |
| Q1 26 | 3.03× | — | ||
| Q4 25 | 0.47× | — | ||
| Q3 25 | 2.21× | -4.17× | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.47× | 1.00× | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | 1.19× | — | ||
| Q2 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OLED
| Material sales | $83.7M | 59% |
| Royalty and license fees | $54.2M | 38% |
| Contract research services | $4.3M | 3% |
PTCT
Segment breakdown not available.
